Message from the CEO
“We are pleased to report another successful year. We closed on a historically strong note with our best quarter ever. The high number of quotes that we sent out during the year proved successful, as our sales increased by 20% in the second half of the year. Total sales increased by 19% during the year, reaching nearly
Peter Nählstedt, President and CEO
Full year 1 January–31 December
- Net sales totaled
SEK 49.9 (41.8) million. - EBITDA amounted to
SEK -10.9 (-15.7) million. - Earnings per share were
SEK -0.91 (-1.03). - Cash and cash equivalents at 31 December amounted to
SEK 17.6 (40.0) million. - The board proposes that no dividend be paid to the Company’s shareholders.
Second half year 1 July–31 December
- Net sales totaled
SEK 26.3 (21.8) million. - EBITDA amounted to
SEK -4.1 (-6.6) million. - Earnings per share were
SEK -0.40 (-0.47).
Significant events during the second half year
SenzaGen received aSEK 1.7 million order from a new customer, a global biotech industry leader.SenzaGen secured a strategically important order from a new customer, a world leader in fast-moving consumer goods (FMCG).SenzaGen continued to collaborate with RIFM in non-animal photosensitization and fragrance safety – receiving a new grant worthSEK 1.6 million .SenzaGen was ranked one ofSweden 's fastest-growing technology companies according to Deloitte's annual ranking, Sweden Technology Fast 50.SenzaGen strengthened its market presence with expanded distribution channels inFrance andIndia .
Significant events after the end of the year
SenzaGen received a follow-on order worthSEK 1.5 million for GARD®skin from a customer in the chemical industry.
Livestream presentation
Time:
Link to the livestream: https://ir.financialhearings.com/senzagen-year-end-report-2023
The presentation can be watched afterwards at SenzaGen’s website: https://senzagen.com/investors/presentations/
© Modular Finance, source